AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 776197 — intervention group
Group type: EXPERIMENTAL
Intervention: Subanaesthetic incremental doses of Althesin
Number of subjects: 61
Study 776197 — intervention group
Group type: COMPARATOR
Intervention: Single sedative dose of diazepam
Number of subjects: 61
Study 30641027 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/Glycopyrronium (IND/GLY) 110/50 μg once daily for 14 days
Number of subjects: 62
Study 30641027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 27609399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 16
Study 27609399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 25593053 — intervention group
Group type: EXPERIMENTAL
Intervention: Transendocardial stem cell injection (TESI) using culture‐expanded mesenchymal stem cells (MSCs)
Number of subjects: 49
Study 23748315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball attachments
Number of subjects: 29
Study 23748315 — intervention group
Group type: COMPARATOR
Intervention: Locator attachments
Number of subjects: 29
Study 21459735 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 37
Study 21459735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 19527481 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart (BIAsp) three times a day (70/30 high-mix before breakfast and lunch, 30/70 before dinner)
Number of subjects: 38
Study 19527481 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart (BIAsp) three times a day
Number of subjects: 38
Study 19527481 — intervention group
Group type: COMPARATOR
Intervention: Biphasic human insulin (BHI) 30/70 twice a day
Number of subjects: 38
Study 16750467 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microg/kg
Number of subjects: 60
Study 16750467 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil 0.25 microg/kg
Number of subjects: 60
Study 14993632 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-dose DEC (6 mg/kg) and Alb (400 mg) for seven days
Number of subjects: 0
Study 14993632 — intervention group
Group type: COMPARATOR
Intervention: Single-dose DEC and Alb
Number of subjects: 0
Study 14993632 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-treatment with single-dose DEC/Alb 12 months after first treatment
Number of subjects: 0
Study 11207085 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.4 g of omega-3 fatty acids daily
Number of subjects: 45
Study 11207085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 9310046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary cemented massive allografts
Number of subjects: 45
Study 9310046 — intervention group
Group type: COMPARATOR
Intervention: Uncemented allografts
Number of subjects: 45
Study 8422853 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine 600 mg
Number of subjects: 12
Study 8422853 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine 400 mg
Number of subjects: 12
Study 8422853 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 300 mg
Number of subjects: 12
Study 8422853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3009634 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV-1 vaccine
Number of subjects: 48
Study 3009634 — intervention group
Group type: COMPARATOR
Intervention: RIT 4237 vaccine
Number of subjects: 48
Study 29858113 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight-control treatment aiming at SDAI ≤ 3.3
Number of subjects: 80
Study 29858113 — intervention group
Group type: COMPARATOR
Intervention: Tight-control treatment aiming at DAS28-CRP < 2.6
Number of subjects: 80
Study 29858113 — intervention group
Group type: EXPERIMENTAL
Intervention: Not achieving sustained SDAI remission at month 6, 9, and 12
Number of subjects: 80
Study 29858113 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid factor >16U
Number of subjects: 80
Study 27487966 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-initiated antiviral therapy with pegylated interferon and ribavirin
Number of subjects: 138
Study 27487966 — intervention group
Group type: COMPARATOR
Intervention: Physician-initiated antiviral therapy with pegylated interferon and ribavirin
Number of subjects: 138
Study 27487966 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-initiated antiviral therapy
Number of subjects: 138
Study 27487966 — intervention group
Group type: COMPARATOR
Intervention: Physician-initiated antiviral therapy
Number of subjects: 138
Study 24759852 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based cognitive behavior therapy (FB-CBT) including exposure plus response prevention
Number of subjects: 127
Study 24759852 — intervention group
Group type: COMPARATOR
Intervention: FB relaxation treatment (FB-RT)
Number of subjects: 127
Study 21969123 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg transdermal nicotine
Number of subjects: 25
Study 21969123 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral mecamylamine
Number of subjects: 25
Study 21969123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 20214326 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuzi Yanzong Decoction (WYD) plus coenzyme Q10
Number of subjects: 30
Study 20214326 — intervention group
Group type: COMPARATOR
Intervention: Coenzyme Q10 alone
Number of subjects: 30
Study 17553503 — intervention group
Group type: EXPERIMENTAL
Intervention: Massaging with dimethyl sulfoxide (DMSO) cream
Number of subjects: 0
Study 17553503 — intervention group
Group type: EXPERIMENTAL
Intervention: Massaging with an indifferent cream
Number of subjects: 0
Study 17553503 — intervention group
Group type: EXPERIMENTAL
Intervention: Position changes only
Number of subjects: 0
Study 15483541 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 50
Study 15483541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11560018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atenolol and enalapril maleate
Number of subjects: 0
Study 11560018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atenolol, enalapril maleate, and hydrochlorothiazide
Number of subjects: 0
Study 10198825 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease group
Number of subjects: 0
Study 10198825 — intervention group
Group type: COMPARATOR
Intervention: Non-demented patients with beta A4 plaques
Number of subjects: 0
Study 10198825 — intervention group
Group type: COMPARATOR
Intervention: Non-demented patients without evidence of frontal plaques
Number of subjects: 0
Study 8167121 — intervention group
Group type: EXPERIMENTAL
Intervention: University of Wisconsin solution
Number of subjects: 10
Study 8167121 — intervention group
Group type: COMPARATOR
Intervention: Buffered cold cardioplegic solution
Number of subjects: 10
Study 3172641 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfone dialyzer (Fresenius F-80)
Number of subjects: 0
Study 3172641 — intervention group
Group type: COMPARATOR
Intervention: Cuprophane dialyzer (Travenol 12.11)
Number of subjects: 0
Study 3172641 — intervention group
Group type: COMPARATOR
Intervention: F-40 dialyzer
Number of subjects: 0
Study 3172641 — intervention group
Group type: COMPARATOR
Intervention: F-60 dialyzer
Number of subjects: 0
Study 6449205 — intervention group
Group type: COMPARATOR
Intervention: 1 g mezlocillin/oxacillin (20% solution) injected intramuscularly
Number of subjects: 20
Study 6449205 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g mezlocillin/oxacillin (25% aqueous solution) injected intramuscularly t.i.d. for about 7 days
Number of subjects: 20
Study 31641754 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ivermectin, diethylcarbamazine, and albendazole (IDA)
Number of subjects: 95
Study 31641754 — intervention group
Group type: COMPARATOR
Intervention: 3 annual doses of ivermectin and albendazole (IA)
Number of subjects: 95
Study 31641754 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of IDA
Number of subjects: 95
Study 31641754 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 95
Study 30182455 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured nursing intervention program for 10 days
Number of subjects: 216
Study 30182455 — intervention group
Group type: COMPARATOR
Intervention: Existing practice nursing care
Number of subjects: 216
Study 28125621 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (viewing a video featuring individuals living in extreme poverty)
Number of subjects: 0
Study 28125621 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 26555225 — intervention group
Group type: EXPERIMENTAL
Intervention: Far-Infrared (FIR) intervention
Number of subjects: 0
Study 26555225 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-Infrared Spectroscopy (NIRS) measurement
Number of subjects: 0
Study 23313835 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback delay of 500ms
Number of subjects: 0
Study 23313835 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus present throughout feedback
Number of subjects: 0
Study 23313835 — intervention group
Group type: EXPERIMENTAL
Intervention: Large variance (SD=150ms) in feedback delay times around a mean delay of 500ms
Number of subjects: 0
Study 23313835 — intervention group
Group type: EXPERIMENTAL
Intervention: Small variance (SD=75ms) in feedback delay times around a mean delay of 500ms
Number of subjects: 0
Study 23313835 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay between stimulus offset and feedback
Number of subjects: 0
Study 21120562 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mCi Yttrium-90 plus 40 mg of triamcinolone hexacetonide (Y/TH Group)
Number of subjects: 84
Study 21120562 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mCi Samarium-153 hydroxyapatite plus 40 mg of triamcinolone hexacetonide (Sm/TH Group)
Number of subjects: 84
Study 21120562 — intervention group
Group type: COMPARATOR
Intervention: 40 mg triamcinolone hexacetonide alone (Control Group)
Number of subjects: 84
Study 19668094 — intervention group
Group type: EXPERIMENTAL
Intervention: Captain's Log cognitive training software (8 weeks, weekly sessions)
Number of subjects: 65
Study 19668094 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment condition
Number of subjects: 65
Study 17500180 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfixed stitches technique
Number of subjects: 160
Study 17500180 — intervention group
Group type: COMPARATOR
Intervention: Milligan‐Morgan procedure
Number of subjects: 160
Study 15259080 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (Group A)
Number of subjects: 94
Study 15259080 — intervention group
Group type: COMPARATOR
Intervention: No plasma exchange (Group B)
Number of subjects: 94
Study 15259080 — intervention group
Group type: COMPARATOR
Intervention: Group I (before plasma exchange availability)
Number of subjects: 94
Study 15259080 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (after plasma exchange availability)
Number of subjects: 94
Study 15259080 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hyperlipidemic pancreatitis patients receiving plasma exchange (Group A)
Number of subjects: 94
Study 15259080 — intervention group
Group type: COMPARATOR
Intervention: Severe hyperlipidemic pancreatitis patients not receiving plasma exchange (Group B)
Number of subjects: 94
Study 11136308 — intervention group
Group type: EXPERIMENTAL
Intervention: Needlescopic cholecystectomy
Number of subjects: 75
Study 11136308 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy
Number of subjects: 75
Study 10048504 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 75 mg once daily (doubled at week 6 if seated diastolic blood pressure >= 90 mmHg)
Number of subjects: 238
Study 10048504 — intervention group
Group type: COMPARATOR
Intervention: Placebo/HCTZ
Number of subjects: 238
Study 8055388 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 125
Study 8055388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 2923821 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetone at 250 ppm
Number of subjects: 137
Study 2923821 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (95%‐0.84 ml/kg)
Number of subjects: 137
Study 2923821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 2923821 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl ethyl ketone (MEK) at 200 ppm
Number of subjects: 137
Study 2923821 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetone at 125 ppm with MEK at 100 ppm
Number of subjects: 137
Study 2923821 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined acetone/MEK exposures
Number of subjects: 137
Study 1053438 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate nasal aerosol (400 micrograms daily)
Number of subjects: 103
Study 30711003 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise intervention
Number of subjects: 30
Study 30711003 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 29033138 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg daily) - overt group
Number of subjects: 46
Study 29033138 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (20 mg daily) - covert group
Number of subjects: 46
Study 29033138 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg daily) - both groups
Number of subjects: 46
Study 29033138 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI outcomes - both groups
Number of subjects: 46
Study 25528758 — intervention group
Group type: EXPERIMENTAL
Intervention: Second generation antipsychotics
Number of subjects: 5233
Study 22703472 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 9
Study 22703472 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 9
Study 22703472 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 9
Study 22703472 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan, Valsartan, Candesartan
Number of subjects: 9
Study 22098139 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal EC
Number of subjects: 38
Study 22098139 — intervention group
Group type: COMPARATOR
Intervention: Triflusal
Number of subjects: 38
Study 20058592 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal methylene blue (MB) injection
Number of subjects: 72
Study 20058592 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 72
Study 17264356 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (vacuum-assisted closure)
Number of subjects: 0
Study 17264356 — intervention group
Group type: COMPARATOR
Intervention: Saline gauze dressings
Number of subjects: 0
Study 14716710 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine plus nizatidine
Number of subjects: 28
Study 14716710 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine plus placebo
Number of subjects: 28
Study 11529631 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc NC scintigraphy
Number of subjects: 51
Study 10101560 — intervention group
Group type: COMPARATOR
Intervention: Standard second reminder letter (R)
Number of subjects: 1500
Study 10101560 — intervention group
Group type: COMPARATOR
Intervention: Standard second reminder letter with health education material (RP)
Number of subjects: 1500
Study 10101560 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard second reminder letter with home visit (RV)
Number of subjects: 1500
Study 8169676 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge teaching and home care in the first 4 weeks after discharge
Number of subjects: 245
Study 8169676 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal acute care visits
Number of subjects: 245
Study 8169676 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant rehospitalizations
Number of subjects: 245
Study 8169676 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant acute care visits
Number of subjects: 245
Study 8169676 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal rehospitalizations
Number of subjects: 245
Study 3356049 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of epidural bupivacaine-fentanyl (initial dose of 5-7 ml, continuous infusion of 3 ml/h)
Number of subjects: 44
Study 3356049 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated injections of epidural bupivacaine-fentanyl (initial dose ranged from 8-12 ml)
Number of subjects: 44
Study 29434529 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (≥2.2 g/kg/d)
Number of subjects: 24
Study 29434529 — intervention group
Group type: COMPARATOR
Intervention: Control diet (habitual diet)
Number of subjects: 24
Study 28299944 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-fermented milk
Number of subjects: 59
Study 28299944 — intervention group
Group type: COMPARATOR
Intervention: Non-fermented placebo milk (PC)
Number of subjects: 59
Study 26625880 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 893
Study 26625880 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg/day
Number of subjects: 893
Study 24260218 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI training system (8-week training comprising 24 half-hour sessions)
Number of subjects: 31
Study 24260218 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI training system
Number of subjects: 31
Study 24260218 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 31
Study 21420316 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling paired with personal digital assistant-based self-monitoring in hemodialysis (HD) patients
Number of subjects: 0
Study 21420316 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling paired with personal digital assistant-based self-monitoring in peritoneal dialysis (PD) patients
Number of subjects: 0
Study 18481712 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with acupoint-injection (adenosine cobaltamine)
Number of subjects: 78
Study 18481712 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture (simple acupuncture)
Number of subjects: 78
Study 18481712 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with acupoint-injection
Number of subjects: 78
Study 18481712 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment within 1 month after operation
Number of subjects: 78
Study 18481712 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment within 2 weeks after attack
Number of subjects: 78
Study 17702710 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 3800
Study 17702710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3800
Study 14637261 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy + atorvastatin (10 mg/day), Group B
Number of subjects: 40
Study 14637261 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy, Group A
Number of subjects: 40
Study 14637261 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (in vitro, 0.1-10 micromol/l)
Number of subjects: 40
Study 10718567 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit learning (concurrent secondary tone-counting task)
Number of subjects: 0
Study 10718567 — intervention group
Group type: COMPARATOR
Intervention: Explicit learning (without secondary task)
Number of subjects: 0
Study 10718567 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed retention test
Number of subjects: 0
Study 9019176 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit-position with PEEP 0 cm H2O
Number of subjects: 34
Study 9019176 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit-position with PEEP 10 cm H2O
Number of subjects: 34
Study 9019176 — intervention group
Group type: COMPARATOR
Intervention: Supine position with PEEP 0 cm H2O
Number of subjects: 34
Study 9019176 — intervention group
Group type: COMPARATOR
Intervention: Supine position with PEEP 10 cm H2O
Number of subjects: 34
Study 9019176 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups with rising PEEP
Number of subjects: 34
Study 8258205 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 40 mg/kg/day for 10 days (Group I: one total dose of amoxicillin and two doses of placebo daily)
Number of subjects: 77
Study 8258205 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 40 mg/kg/day for 10 days (Group II: three divided doses of amoxicillin daily)
Number of subjects: 77
Study 8258205 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 77
Study 8258205 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group I and Group II)
Number of subjects: 77
Study 3896354 — intervention group
Group type: EXPERIMENTAL
Intervention: Masker treatment
Number of subjects: 0
Study 3896354 — intervention group
Group type: COMPARATOR
Intervention: Control group with no instrumental treatment
Number of subjects: 0
Study 3896354 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aid or combination instrument treatment
Number of subjects: 0
Study 31629573 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril, 10mg, and folic acid, 0.8mg
Number of subjects: 1374
Study 31629573 — intervention group
Group type: COMPARATOR
Intervention: enalapril, 10mg alone
Number of subjects: 1374
Study 30238061 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing + Enhanced Community Services (MI + ECS)
Number of subjects: 579
Study 30238061 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Community Services (ECS)
Number of subjects: 579
Study 26089210 — intervention group
Group type: EXPERIMENTAL
Intervention: Active supplement (novel, multi-component formula containing xanthophyll pigments, antioxidants and selected botanical extracts)
Number of subjects: 0
Study 26089210 — intervention group
Group type: EXPERIMENTAL
Intervention: Active supplement
Number of subjects: 0
Study 26089210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24491793 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped wedge design intervention
Number of subjects: 0
Study 23131884 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (2000 mg/d)
Number of subjects: 23